<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968419</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885V2201C</org_study_id>
    <secondary_id>2018-004813-42</secondary_id>
    <nct_id>NCT03968419</nct_id>
  </id_info>
  <brief_title>This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.</brief_title>
  <acronym>CANOPY-N</acronym>
  <official_title>A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment,&#xD;
      either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR&#xD;
      rate of pembrolizumab as a single agent. Additionally the dynamics of the tumor&#xD;
      microenvironment changes on treatment by comparing pre-, on- and post-treatment samples will&#xD;
      be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">March 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Pathological Response (MPR) rate based on Central review</measure>
    <time_frame>At time of surgery (approximately 4 - 6 weeks after first dose)</time_frame>
    <description>This will assess the rate of MPR at the time of surgery in all participants randomized to canakinumab alone and in combination with pembrolizumab arms based on central review.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA) of canakinumab</measure>
    <time_frame>Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), at end of treatment &amp; then at 26, 78 and 130 days after last dose</time_frame>
    <description>To characterize the prevalence and incidence of immunogenicity (anti-drug antibodies, ADA) of canakinumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA) of pembrolizumab</measure>
    <time_frame>Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), at end of treatment and then at 26 days after last dose</time_frame>
    <description>To characterize the prevalence and incidence of immunogenicity (anti-drug antibodies, ADA) of pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) per investigator assessment using RECIST v1.1</measure>
    <time_frame>From date of randomization to date of surgery up to 6 weeks</time_frame>
    <description>ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum canakinumab concentration</measure>
    <time_frame>Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), at end of treatment &amp; then at 26, 78 and 130 days after last dose</time_frame>
    <description>To characterize the pharmacokinetics of canakinumab therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum pembrolizumab concentration</measure>
    <time_frame>Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), end of infusion on Day 1 Cycle 1, at end of treatment and then at 26 days after last dose</time_frame>
    <description>To characterize the pharmacokinetics of pembrolizumab therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical feasibility rate</measure>
    <time_frame>4 to 6 weeks after first dose</time_frame>
    <description>To assess the rate of the surgical feasibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR based on central review</measure>
    <time_frame>At time of surgery (approximately 4 - 6 weeks after first dose)</time_frame>
    <description>This will assess the rate of MPR at the time of surgery in all participants randomized to pembrolizumab monotherapy arm based on central review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR based on local review</measure>
    <time_frame>At time of surgery (approximately 4 - 6 weeks after first dose)</time_frame>
    <description>This will assess the rate of MPR at the time of surgery in all randomized participants based on local review in each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in MPR rate based on central review</measure>
    <time_frame>At time of surgery (approximately 4 - 6 weeks after first dose)</time_frame>
    <description>This will estimate the difference in MPR and posterior probability of the difference in MPR â‰¥ 10% between participants randomized to canakinumab + pembrolizumab combination and pembrolizumab alone based on central review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR rate based on the levels of biomarkers</measure>
    <time_frame>From date of randomization to 130 days after last dose of drug</time_frame>
    <description>Biomarkers include PD-L1, CD8, hs-CRP, hs-IL-6</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>canakinumab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive canakinumab (ACZ885) prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>canakinumab + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive canakinumab (ACZ885) and pembrolizumab prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pembrolizumab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive 2 doses of pembrolizumab prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>canakinumab</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>canakinumab + pembrolizumab</arm_group_label>
    <arm_group_label>canakinumab monotherapy</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>200mg administered intravenously every 3 weeks</description>
    <arm_group_label>canakinumab + pembrolizumab</arm_group_label>
    <arm_group_label>pembrolizumab monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:&#xD;
&#xD;
          -  Histologically confirmed NSCLC stage IB-IIIA (per AJCC 8th edition), deemed suitable&#xD;
             for primary resection by treating surgeon, except for N2 and T4 tumors.&#xD;
&#xD;
          -  Subject must be eligible for surgery and with a planned surgical resection in&#xD;
             approximately 4-6 weeks (after the first dose of study treatment).&#xD;
&#xD;
          -  A mandatory newly obtained tissue biopsy from primary site is required for study&#xD;
             enrollment. An archival biopsy is also acceptable if obtained up to 5 months before&#xD;
             first day of study treatment and if the subject did not go through antineoplastic&#xD;
             systemic therapies between biopsy collection date and beginning of study treatment.&#xD;
&#xD;
        Note: Aspirates will not be accepted.&#xD;
&#xD;
        - Eastern Cooperative oncology group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
        Key exclusion criteria:&#xD;
&#xD;
          -  Subjects with unresectable or metastatic disease.&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to monoclonal antibodies, which in the&#xD;
             opinion of the investigator may pose an increased risk of serious infusion reaction&#xD;
&#xD;
          -  Subjects who received prior systemic therapy (including chemotherapy, other&#xD;
             anti-cancer therapies and any other antibody or drug specifically targeting T-cell&#xD;
             co-stimulation or immune checkpoint pathways) in the past 3 years before screening&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             prior to randomization. Control of the disorder with replacement therapy is permitted&#xD;
&#xD;
          -  Subject with suspected or proven immunocompromised state or infections&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Taylor</last_name>
      <phone>480-301-8000</phone>
      <email>Taylor.Marissa@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Panos Savvides</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rena Thornton</last_name>
      <phone>479-872-8130</phone>
      <email>rthornton@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>Eric S Schaefer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Oncology Hematology</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy K Gelfand</last_name>
      <phone>858-622-5855</phone>
      <email>NGelfand@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Amy B Cummings</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Sakin</last_name>
      <phone>614-657-1463</phone>
      <email>sarah.sakin@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>John Vu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsteen Lugtu</last_name>
      <phone>773-702-8582</phone>
      <email>klugtu@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Everett Vokes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Neurology Dept.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Kocher</last_name>
      <phone>913-588-3968</phone>
      <email>dkocher@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jun Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY - Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>315-464-9006</phone>
    </contact>
    <investigator>
      <last_name>Stephen Graziano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute SC 1</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Tezber</last_name>
      <email>kendra.tezber@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Raghava Induru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital / Methodist Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>*see various departments*</phone>
    </contact>
    <investigator>
      <last_name>Eric Bernicker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kaminski</last_name>
      <phone>608-262-7202</phone>
      <email>agkaminski@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Ticiana Leal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <state>Herault</state>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torokbalint</city>
        <state>Pest</state>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hertogenbosch</city>
        <zip>5200</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaen</city>
        <state>Andalucia</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sakarya</city>
        <zip>54290</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sihhiye / Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACZ885</keyword>
  <keyword>canakinumab</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>NSCLC</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>early stage NSCLC</keyword>
  <keyword>squamous</keyword>
  <keyword>non-squamous,</keyword>
  <keyword>MPR</keyword>
  <keyword>major pathological response</keyword>
  <keyword>hs-CRP</keyword>
  <keyword>PD-L1</keyword>
  <keyword>hsCRP</keyword>
  <keyword>surgery</keyword>
  <keyword>neo-adjuvant</keyword>
  <keyword>neo adjuvant</keyword>
  <keyword>CD8</keyword>
  <keyword>hs-IL-6</keyword>
  <keyword>CANOPY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

